Related references
Note: Only part of the references are listed.Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
Steven Lemery et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
L. Paz-Ares et al.
ESMO OPEN (2022)
Topotecan or other agents as second‑line therapy for relapsed small‑cell lung cancer: A meta‑analysis of randomized studies
Fausto Petrelli et al.
Molecular and Clinical Oncology (2021)
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Fiona Blackhall et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Lurbinectedin in the treatment of relapsed small cell lung cancer
Javier Baena et al.
FUTURE ONCOLOGY (2021)
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study
Melissa L. Johnson et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Dangling Accelerated Approvals in Oncology
Julia A. Beaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.
Martin Wermke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer
Susanne Hipp et al.
CLINICAL CANCER RESEARCH (2020)
International real-world study of DLL3 expression in patients with small cell lung cancer
Federico Rojo et al.
LUNG CANCER (2020)
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
Megumi Furuta et al.
CANCER SCIENCE (2019)
Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics
Richard S. P. Huang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
DLL3: an emerging target in small cell lung cancer
Dwight H. Owen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
Wade H. Aaron et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
Kentaro Tanaka et al.
LUNG CANCER (2018)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Jing Shan Lim et al.
NATURE (2017)
Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages
Shuncong Wang et al.
SCIENTIFIC REPORTS (2017)
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu et al.
CLINICAL PHARMACOKINETICS (2016)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Share Paper
